PURPOSE: The aim of this study was to assess the utility of positron emission tomography/computed tomography (PET/CT) for the investigation of patients with suspected paraneoplastic neurologic syndrome (PNS). MATERIALS AND METHODS: We reviewed the whole-body fluorodeoxyglucose (FDG) PET/CT studies (ordered by the neurology department) performed at our hospital between December 2005 and November 2010; 27 cases (16 men, 11 women; mean age, 65 years) who were suspected of having PNS were selected. RESULTS: Of the 27 patients, 6 (22%) had an abnormal FDG uptake. Of these 6 patients, 5 (19%) were histologically confirmed as having a malignancy. Of the 27 patients, 7 were tested for the presence of well-characterized paraneoplastic antibodies (anti-Hu, anti-Ri, anti-Yo); 1 had anti-Hu, but the patient did not have an abnormal FDG uptake or malignancy. CONCLUSIONS: PET/CT may be a useful screening tool for patients with clinically suspected PNS who do not exhibit well-characterized paraneoplastic antibodies. Therefore, we recommended that PET/CT should be performed for patients with clinically suspicious PNS regardless of the presence of well-characterized paraneoplastic antibodies.
PURPOSE: The aim of this study was to assess the utility of positron emission tomography/computed tomography (PET/CT) for the investigation of patients with suspected paraneoplastic neurologic syndrome (PNS). MATERIALS AND METHODS: We reviewed the whole-body fluorodeoxyglucose (FDG) PET/CT studies (ordered by the neurology department) performed at our hospital between December 2005 and November 2010; 27 cases (16 men, 11 women; mean age, 65 years) who were suspected of having PNS were selected. RESULTS: Of the 27 patients, 6 (22%) had an abnormal FDG uptake. Of these 6 patients, 5 (19%) were histologically confirmed as having a malignancy. Of the 27 patients, 7 were tested for the presence of well-characterized paraneoplastic antibodies (anti-Hu, anti-Ri, anti-Yo); 1 had anti-Hu, but the patient did not have an abnormal FDG uptake or malignancy. CONCLUSIONS: PET/CT may be a useful screening tool for patients with clinically suspected PNS who do not exhibit well-characterized paraneoplastic antibodies. Therefore, we recommended that PET/CT should be performed for patients with clinically suspicious PNS regardless of the presence of well-characterized paraneoplastic antibodies.
Authors: Ana María García Vicente; Roberto C Delgado-Bolton; Mariano Amo-Salas; Jesús López-Fidalgo; Ana Paula Caresia Aróztegui; José Ramón García Garzón; Javier Orcajo Rincón; María José García Velloso; María de Arcocha Torres; Soledad Alvárez Ruíz Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-27 Impact factor: 9.236
Authors: F J Pena Pardo; A M García Vicente; M Amo-Salas; J F López-Fidalgo; J A Garrido Robles; J Á de Ayala Fernández; P Del Saz Saucedo; M Muñoz Pasadas; A Soriano Castrejón Journal: Clin Transl Oncol Date: 2016-05-02 Impact factor: 3.405
Authors: N Schramm; A Rominger; C Schmidt; J N Morelli; C Schmid-Tannwald; F G Meinel; M F Reiser; C Rist Journal: Eur J Nucl Med Mol Imaging Date: 2013-03-16 Impact factor: 9.236
Authors: Manas Kumar Sahoo; S T Arunraj; Achal Kumar Srivastava; Ranjit Kumar Sahoo; Rakesh Kumar; Chandrasekhar Bal Journal: Indian J Nucl Med Date: 2016 Oct-Dec
Authors: Knut Kurt William Kampe; Roman Rotermund; Milena Tienken; Götz Thomalla; Marc Regier; Susanne Klutmann; Stefan Kluge Journal: Front Neurol Date: 2017-02-14 Impact factor: 4.003